Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 1999

View Archived Issues

Forest restructures Climara agreement with Berlex

Medeva announces half-year highlights

Early-stage R&D at BioCryst: Q2 highlights

Rochester Medical's female incontinence device receives CE mark

Avant's complement-selectin inhibitor reduces brain damage in mouse model of stroke

Eligix cleared to initiate pivotal trial of DLI purification technology

Kos and Knoll reach definitive agreement for promotion of antihypertensive drugs

Kinetek initiates development of ILK and PKB inhibitors for cancer therapy

Biovail to acquire Fuisz

FDA approves pediatric formulation of Topamax

Heterocyclic compounds as potent and selective NK2 antagonists

Asmarine A and B: novel cytotoxic alkaloids produced by marine organism

Novel epipodophyllotoxin derivatives with excellent antitumor activity

Potassium channel modulators designed at Novo Nordisk especially for endocrine disorders

Dopaminergic agents for schizophrenia and Parkinson's disease from AHP

Warner-Lambert patents new series of dopamine D4 antagonists

International patent recently published covering AstraZeneca PKC inhibitors

Mechanism of gastroprotective effects of lafutidine determined in in vitro and in vivo studies

Postischemic YM-872 investigated for neuroprotective effects in model of acute ischemic stroke

NS-49: preclinical pharmacokinetics of potential new agent for stress incontinence

Shire and Roberts enter definitive merger agreement

Elan and Merck establish second technology transfer and license agreement

Schering-Plough launches Rebetol combination therapy in the U.K.

FDA advisory committee OKs safety and efficacy of Rapamune

FDA approves Relenza for treatment of influenza

Second U.S. patent covers GVAX cancer vaccine technology; positive lung cancer results reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...